Maxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and a price target of $4.

May 13, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chemomab Therapeutics receives a Buy rating from Maxim Group with a price target of $4, indicating a positive outlook from the analyst.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually leads to increased investor interest and can positively impact the stock price in the short term. Given the direct mention and the positive nature of the coverage, it's likely to have a favorable effect on Chemomab Therapeutics' stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100